Quarterly ResultMay 12, 2026, 04:38 PM
Sanuwave Q1 Revenue $9.6M, up 3.1%; Projects Q2 Revenue up 10-15%
AI Summary
Sanuwave Health, Inc. reported Q1 2026 revenues of $9.6 million, a 3.1% increase year-over-year, marking its highest Q1 revenue in company history. Despite a GAAP operating loss of $1.1 million and a decrease in gross margin to 77.3%, the company saw a significant improvement in net loss to $1.4 million from $6.1 million in Q1 2025. Management expressed increasing optimism, citing a recovery starting in February, and provided Q2 2026 revenue guidance of $11.1 to $11.6 million, representing a 10-15% increase.
Key Highlights
- Q1 2026 revenue increased 3.1% to $9.6 million, the highest Q1 in company history.
- GAAP Operating Loss was $1.1 million in Q1 2026, a $1.7 million swing from Q1 2025 operating income.
- Net loss improved to $1.4 million in Q1 2026 from $6.1 million in Q1 2025.
- Gross margin decreased to 77.3% in Q1 2026 from 79.0% in Q1 2025.
- Ultramist® consumables revenue grew 15.0% to $6.7 million year-over-year.
- Company forecasts Q2 2026 revenue of $11.1-$11.6 million, up 10-15% from Q2 2025.
- Reiterated full year 2026 revenue guidance of $51.0-$55.0 million, up 16-25% from 2025.
- Net cash provided by operating activities was $397 thousand, a positive swing from Q1 2025.